VKTX
Viking Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 10 ▲ 1 insider buy $149.9K at $33.50
- May 28 Lake Street initiates
- Jul 29 ▼ 3 insiders sell $6.3M at $33.35
- Sep 22 ▲ Viking Therapeutics announced positive topline results from its VK27…
- Sep 23 ▼ Viking Therapeutics filed a preliminary prospectus supplement for an…
- Sep 25 ▼ Viking Therapeutics is conducting a dilutive follow-on offering of 7…
- Sep 28 Viking Therapeutics issued $258.75M in 2.00% convertible senior note…
- Oct 15 UBS initiates
- Oct 28 ▼ Earnings: VKTX Q3 2026 Earnings: EPS $-1.55 (-42.6% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $149.9K at an average $33.50. 3 insiders sold $6.3M. Price is 20% below their cost.
- InstitutionsMIXED
Q3 2026: 38 added (0 new), 27 trimmed or exited.
- AnalystsBULLISH
24 of 27 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −5.4% to 24.16M shares. 5.4 days to cover, ≈18.9% of shares.
- TrendRANGE
8% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 24.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $321.0M |
| BARCLAYS PLC | DOUBLED | $28.4M |
| Bank of New York Mellon Corp | ADD | $22.4M |
| PRINCIPAL FINANCIAL GROUP INC | ADD | $21.9M |
| JANE STREET GROUP, LLC | TRIM | $15.9M |
| Pictet Asset Management Holding SA | TRIM | $15.9M |
| MARSHALL WACE, LLP | DOUBLED | $15.7M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $12.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analystsPrice is below the lowest target. Median implies +254%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 30, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 20, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 15, 2026 | UBS INITIATE | Buy |
| Oct 7, 2026 | Truist Securities MAINTAIN | Buy |
| Sep 23, 2026 | Truist Securities MAINTAIN | Buy |
| Aug 11, 2026 | JP Morgan MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kelly-Gemmell Dorothy Elizabeth Director Aug 1, 2026 | AWARD | 40,800 sh |
Kelly-Gemmell Dorothy Elizabeth Director Aug 1, 2026 | AWARD | 6,333 sh |
Mancini Marianna Chief Operating Officer Jul 29, 2026 | SELL | $609.6K |
ZANTE GREG Chief Financial Officer Jul 29, 2026 | SELL | $710.1K |
Lian Brian President & CEO Jul 29, 2026 | SELL | $4.9M |
Mancini Marianna Chief Operating Officer Jul 28, 2026 | AWARD | 31,667 sh |
ZANTE GREG Chief Financial Officer Jul 28, 2026 | AWARD | 31,667 sh |
Lian Brian President & CEO Jul 28, 2026 | AWARD | 221,667 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 1 bullish · 4 bearish · 1 mixed · 7 neutral- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 9,539,067…
Fidelity's increased passive stake to 7.7% signals continued institutional interest, but as a 13G filer there is no activist intent. Monitor for any future conversion to a 13D filing, which would…
- NEUTRAL 8-KOct 28, 2026
Viking Therapeutics reported Q3 2026 net loss of $183.2M ($1.55/share), wider than the $90.8M loss…
The EPS miss and widening losses reflect heavy investment in Phase 3 trials and commercial infrastructure, typical for a pre-revenue biotech. The $960M cash runway funds multiple catalysts through…
- BEARISH INST-CLUSTEROct 23, 2026
Viking Therapeutics' Q3 2026 institutional 13F cluster shows net selling pressure: 4 asset…
Monitor upcoming Q4 2026 13F filings for continued institutional exodus. The absence of activist or hedge fund interest suggests the post-offering thesis lacks a near-term catalyst. Wasatch's large…
- NEUTRAL PRESS-RELEASEOct 21, 2026
Viking Therapeutics, Inc announced it will report its Q3 2026 results on October 28, 2026.
All VKTX filing & press-release reports (13)
- SC 13G/A reportNov 5, 2026
- 8-K reportOct 28, 2026
- INST-CLUSTER reportOct 23, 2026
- PRESS-RELEASE reportOct 21, 2026
- 8-K reportSep 28, 2026
- 424B5 reportSep 24, 2026
- 424B5 reportSep 24, 2026
- 424B5 reportSep 23, 2026
- 424B5 reportSep 23, 2026
- 8-K reportSep 22, 2026
- CLUSTER reportJul 29, 2026
- CLUSTER reportJul 29, 2026
- DEFA14A reportApr 1, 2026